The introduction of amivantamab presents a exciting development for people battling cancers exhibiting c-MET overexpression. This novel therapeutic, a targeted agent of multiple MET kinase and human epidermal growth factor receptor 2 (HER2), revealed encouraging efficacy in research studies, particularly in patients whose tumors display detectable